[go: up one dir, main page]

AR053711A1 - Combinacion de vacunas para circovirus porcina y helicobacter y metodos de utilizacion - Google Patents

Combinacion de vacunas para circovirus porcina y helicobacter y metodos de utilizacion

Info

Publication number
AR053711A1
AR053711A1 ARP060101493A ARP060101493A AR053711A1 AR 053711 A1 AR053711 A1 AR 053711A1 AR P060101493 A ARP060101493 A AR P060101493A AR P060101493 A ARP060101493 A AR P060101493A AR 053711 A1 AR053711 A1 AR 053711A1
Authority
AR
Argentina
Prior art keywords
helicobacter
vaccines
antigen
porcine
circovirus
Prior art date
Application number
ARP060101493A
Other languages
English (en)
Inventor
John Ellis
Catherine Charreyre
Oliver Michel Martinon
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Ltd filed Critical Merial Ltd
Publication of AR053711A1 publication Critical patent/AR053711A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2750/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente se basa en especies del gen de Helicobacter que están asociadas con la ulceracion gastroesofágica en cerdos. En particular, se ha utilizado una especie, H. cerdo, como fuente de material antigénico para el desarrollo de vacunas para el tratamiento de trastornos gastroesofágicos. Más ventajosamente, el Helicobacter y circovirus porcino asociados con el PMWS (síndrome de demedro multisistémico post destete) en cerdos son utiles para brindar vacunas de combinacion, a través de las cuales los inmunogenos derivados de ambos tipos de patogenos pueden cosuministrarse al animal meta par estimular la generacion de anticuerpos protectores e inmunidad. Por lo tanto, brinda vacunas que son utiles para el tratamiento de la ulceracion gastroesofágica y PMWS en porcinos. Por consiguiente, la presente incluye composiciones inmunogénicas y vacunas multivalentes, kits multivalentes, y métodos de inmunizacion o vacunacion combinados que hacen posible utilizar dichos programas de inmunizacion o vacunacion combinados. Reivindicacion 1: Una composicion inmunogénica para provocar una respuesta inmunologica contra una especie Helicobacter y circovirus porcino que comprende al menos un antígeno de Helicobacter y al menos un antígeno de circovirus porcino y un vehículo o excipiente veterinariamente aceptable. Reivindicacion 17: Un método para inducir una respuesta inmunologica contra una cepa de Helicobacter y un circovirus porcino, que consiste en administrar a un porcino una composicion inmunogénica de acuerdo con cualquiera de las reivindicaciones 1 a 16. Reivindicacion 18: Un kit para preparar una composicion inmunogénica de acuerdo con la reivindicacion 1 que comprende (i) al menos un antígeno de Helicobacter y (ii) al menos un antígeno de circovirus porcino, donde (i) y ii) se envasan por separado.
ARP060101493A 2005-04-15 2006-04-17 Combinacion de vacunas para circovirus porcina y helicobacter y metodos de utilizacion AR053711A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/107,219 US20060029617A1 (en) 1997-10-03 2005-04-15 Porcine circovirus and Helicobacter combination vaccines and methods of use

Publications (1)

Publication Number Publication Date
AR053711A1 true AR053711A1 (es) 2007-05-16

Family

ID=37027631

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101493A AR053711A1 (es) 2005-04-15 2006-04-17 Combinacion de vacunas para circovirus porcina y helicobacter y metodos de utilizacion

Country Status (9)

Country Link
US (1) US20060029617A1 (es)
EP (1) EP1871884A2 (es)
CN (1) CN101198699A (es)
AR (1) AR053711A1 (es)
BR (1) BRPI0607551A2 (es)
CA (1) CA2604705A1 (es)
CL (1) CL2006000880A1 (es)
TW (1) TW200719912A (es)
WO (1) WO2006113372A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ505008A (en) * 1997-12-11 2003-07-25 Univ Saskatchewan Porcine circovirus (PCV) isolates from pigs displaying postweaning multisystemic wasting syndrome virus
CN102078622A (zh) 2004-08-13 2011-06-01 巴里.J.马沙尔 细菌递送系统
US8029777B2 (en) * 2004-08-13 2011-10-04 Marshall Barry J Helicobacter system and uses thereof
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
CN103536914B (zh) 2005-12-29 2015-11-11 贝林格尔.英格海姆维特梅迪卡有限公司 多价pcv2免疫原性组合物和制备此类组合物的方法
KR20140019479A (ko) 2005-12-29 2014-02-14 베링거잉겔하임베트메디카인코퍼레이티드 돼지에서 임상 증상을 경감시키기 위한 ｐｃｖ2 면역원성 조성물의 용도
WO2008064299A2 (en) * 2006-11-22 2008-05-29 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing porcine circovirus-associated disease outbreaks
EP2101815A4 (en) 2006-12-11 2010-10-06 Boehringer Ingelheim Vetmed EFFICIENT PROCESS FOR THE TREATMENT OF PORCINE CIRCOVIRUS AND LAWSONIA INTRACELLULARIS INFECTIONS
CA2670836C (en) * 2006-12-15 2018-09-04 Boehringer Ingelheim Vetmedica, Inc. Treatment of pigs with pcv2 antigen
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) * 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
AU2008347235A1 (en) * 2007-12-31 2009-07-16 Boehringer Ingelheim Vetmedica, Inc. PCV2 ORF2 virus like particle with foreign amino acid insertion
KR20100113582A (ko) * 2008-01-23 2010-10-21 베링거잉겔하임베트메디카인코퍼레이티드 Ｐｃｖ2 마이코플라즈마 히오뉴모니에 면역원성 조성물 및 당해 조성물의 생산 방법
EP2254595A4 (en) * 2008-02-15 2012-12-05 Boehringer Ingelheim Vetmed METHODS AND COMPOSITIONS FOR REDUCING THE IMPACT OF ENTERIC DISEASES
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
CN102973932A (zh) * 2011-09-07 2013-03-20 普莱柯生物工程股份有限公司 猪繁殖与呼吸综合征、猪圆环病毒病与猪伪狂犬病三联灭活疫苗以及其制备方法
CN102406936A (zh) * 2011-11-22 2012-04-11 青岛易邦生物工程有限公司 一种鸡传染性鼻炎灭活疫苗佐剂
CN103893749A (zh) * 2012-12-29 2014-07-02 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
CN103920146A (zh) * 2013-01-14 2014-07-16 普莱柯生物工程股份有限公司 猪圆环病毒ⅱ型与猪伪狂犬病二联疫苗及其制备方法和应用
DK3052516T3 (da) 2013-10-02 2020-03-23 Boehringer Ingelheim Animal Health Usa Inc PCV2-ORF2-proteinvariant og viruslignende partikler sammensat deraf
RO132299A3 (ro) 2017-06-06 2018-12-28 Fântână Raul Sorin Compoziţie şi metodă de preparare şi evaluare a unui imunogen complex numit i-spga, destinat producerii de proteine imunologic active ()

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA78180C2 (uk) * 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
AU2004209985B2 (en) * 2003-02-03 2008-09-18 Cerebus Biologicals, Inc. Methods for treating, preventing and detecting Helicobacter infection

Also Published As

Publication number Publication date
WO2006113372A2 (en) 2006-10-26
EP1871884A2 (en) 2008-01-02
CA2604705A1 (en) 2006-10-26
CL2006000880A1 (es) 2009-08-07
WO2006113372A3 (en) 2007-06-14
BRPI0607551A2 (pt) 2009-09-15
TW200719912A (en) 2007-06-01
US20060029617A1 (en) 2006-02-09
CN101198699A (zh) 2008-06-11

Similar Documents

Publication Publication Date Title
AR053711A1 (es) Combinacion de vacunas para circovirus porcina y helicobacter y metodos de utilizacion
CO6260103A2 (es) Composiciones que comprenden antigenos neumococidos
EE200100203A (et) Meetod immuunvastuse indutseerimiseks polüpeptiidse antigeeni vastu ja rakuga seotud polüpeptiidse antigeeni mahasurumiseks loomorganismil, selle meetodi kasutamine eesnäärme- ja rinnavähi raviks ning immunogeenne kompositsioon
NO20082472L (no) Vaksinesammensetninger omfattende en saponin adjuvant
MX2018007860A (es) Vacunas recombinantes contra el zika.
CO5700788A2 (es) Composiciones y metodos para inmunoterapia especifica de wt1
MX2007015933A (es) Metodos y composiciones para generar respuestas inmunes multivalentes contra espitopes dominantes y subdominantes, expresados en celulas cancerigenas y estromas tumorales.
PE20030285A1 (es) Vacunacion en dosis unica con mycoplasma hyopneumoniae
NO20015073D0 (no) Vaksiner
MY150706A (en) Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant
MA32819B1 (fr) Vaccin combine notamment contre la coqueluche acellulaire
AR061152A1 (es) Vacuna recombinante contra virus de la lengua azul
DK1898948T3 (da) Polyriboinosinsyre-polyribocytidylsyre-baseret adjuvans
AR102548A1 (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
RU2014127714A (ru) ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
AR109538A1 (es) Vacuna contra la gripe porcina
CL2021003211A1 (es) Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018)
AR126891A2 (es) Vacunas de subunidades de rotavirus, métodos de preparación y uso de las mismas
BR112017005120A2 (pt) composição, conjugado terapêutico isolado, método para tratar câncer em um paciente necessitando do mesmo, método para induzir anticorpos em um indivíduo, composição farmacêutica e método para induzir anticorpos em um indivíduo
BR112023019301A2 (pt) Formulações de vacina de coronavírus
CO2021005066A2 (es) Vacuna de ibv 4/91 con proteína espicular heteróloga
CY1112575T1 (el) Βελτιωμενα αδρανοποιημενα εμβολια fcv
CY1112149T1 (el) Μειωση της παρεμβολης μεταξυ επικουρων που περιεχουν ελαιο και αντιγονων που περιεχουν τασιενεργο
MX2021012051A (es) Vacunas para circovirus porcino tipo 3 (pcv3), y produccion y sus usos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure